27335087|t|Fuzheng Qingjie Granules Inhibit Growth of Hepatoma Cells via Inducing Mitochondria -Mediated Apoptosis and Enhancing Immune Function
27335087|a|Fuzheng Qingjie (FZQJ) granules, a compound Chinese medicine, have been used as an adjuvant therapy for alimentary tract cancers. However, the underlying anticancer mechanisms are still not well understood. In the present study, HepG2 cells were treated with FZQJ - containing serum. Cell proliferation was evaluated using MTT assay. Apoptosis was analyzed using a flow cytometer. Cell ultrastructure was observed under a transmission electron microscope. The mitochondrial membrane potential (Δψ) was examined with JC-1 dye. In H22 tumor-bearing mice, CD4(+) T cells, CD8(+) T cells, CD3(+) T cells, and natural killer cells (NK) in peripheral blood were evaluated cytometrically. Interleukin (IL)-2 and tumor necrosis factor (TNF)-α levels were measured using radioimmunoassay .The mRNA levels of Bax and Bcl-2 were examined by reverse transcription-polymerase chain reaction. The protein levels of Bax, Bcl-2, cytochrome C, caspase 3 and 9, PARP, and CD69 were examined by Western blotting. The apoptotic cells in tissues were observed using TUNEL method. Alanine transaminase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN), and creatinine (CRE) were detected by an automatic biochemical analyzer. The results showed that FZQJ - containing serum remarkably inhibited proliferation of HepG2 cells in dose - and time - dependent manners, induced HepG2 cell apoptosis and caused a decrease of Δψ. Analysis of tumor tissue showed that FZQJ - induced apoptosis was accompanied by downregulation of Bcl-2 and upregulation of Bax, release of cytochrome c, activation of caspase 3 and 9, and cleavage of PARP. In addition, FZQJ increased the percentages of CD4(+) T and NK cells, the ratio of CD4(+) / CD8(+) T cells as well as the levels of serum TNF-α. FZQJ also increased CD69 expression in tumor tissue. No hepatorenal toxicity was observed in H22 tumor-bearing mice. These results indicated that FZQJ could inhibit the growth of hepatoma cells via regulating immune function and inducing mitochondria mediated apoptosis.
27335087	0	24	Fuzheng Qingjie Granules	T103	UMLS:C0574031
27335087	33	39	Growth	T038	UMLS:C0220844
27335087	71	83	Mitochondria	T017	UMLS:C0026237
27335087	94	103	Apoptosis	T038	UMLS:C0162638
27335087	118	133	Immune Function	T038	UMLS:C1817756
27335087	134	149	Fuzheng Qingjie	T103	UMLS:C0574031
27335087	150	165	(FZQJ) granules	T103	UMLS:C0574031
27335087	169	177	compound	T103	UMLS:C1706082
27335087	217	233	adjuvant therapy	T058	UMLS:C0677850
27335087	238	254	alimentary tract	T022	UMLS:C0017189
27335087	255	262	cancers	T038	UMLS:C0006826
27335087	288	298	anticancer	T033	UMLS:C0243095
27335087	356	361	study	T062	UMLS:C2603343
27335087	363	374	HepG2 cells	T017	UMLS:C2717940
27335087	393	397	FZQJ	T103	UMLS:C0574031
27335087	411	416	serum	T031	UMLS:C0229671
27335087	418	436	Cell proliferation	T038	UMLS:C0596290
27335087	441	450	evaluated	T058	UMLS:C0220825
27335087	457	466	MTT assay	T062	UMLS:C2986858
27335087	468	477	Apoptosis	T038	UMLS:C0162638
27335087	482	490	analyzed	T062	UMLS:C0936012
27335087	499	513	flow cytometer	T074	UMLS:C0180279
27335087	556	588	transmission electron microscope	T074	UMLS:C0262880
27335087	594	626	mitochondrial membrane potential	T038	UMLS:C1720920
27335087	628	630	Δψ	T038	UMLS:C1720920
27335087	636	644	examined	T033	UMLS:C0332128
27335087	650	658	JC-1 dye	T103	UMLS:C0013343
27335087	663	685	H22 tumor-bearing mice	T038	UMLS:C1512411
27335087	687	701	CD4(+) T cells	T017	UMLS:C0039215
27335087	703	717	CD8(+) T cells	T017	UMLS:C0242629
27335087	719	733	CD3(+) T cells	T017	UMLS:C1267816
27335087	739	759	natural killer cells	T017	UMLS:C0022688
27335087	761	763	NK	T017	UMLS:C0022688
27335087	768	784	peripheral blood	T031	UMLS:C0229664
27335087	800	814	cytometrically	T074	UMLS:C0180279
27335087	816	834	Interleukin (IL)-2	T103	UMLS:C0021756
27335087	839	860	tumor necrosis factor	T103	UMLS:C0041368
27335087	861	868	(TNF)-α	T103	UMLS:C0041368
27335087	896	912	radioimmunoassay	T058	UMLS:C0034580
27335087	918	922	mRNA	T103	UMLS:C0035696
27335087	933	936	Bax	T017	UMLS:C0812198
27335087	941	946	Bcl-2	T017	UMLS:C0376515
27335087	952	960	examined	T033	UMLS:C0332128
27335087	964	1011	reverse transcription-polymerase chain reaction	T062	UMLS:C0599161
27335087	1017	1024	protein	T103	UMLS:C0033684
27335087	1035	1038	Bax	T103	UMLS:C0219474
27335087	1040	1045	Bcl-2	T103	UMLS:C0210955
27335087	1047	1059	cytochrome C	T103	UMLS:C0010749
27335087	1061	1070	caspase 3	T103	UMLS:C0291573
27335087	1075	1076	9	T103	UMLS:C0910167
27335087	1078	1082	PARP	T103	UMLS:C0032405
27335087	1088	1092	CD69	T103	UMLS:C0108800
27335087	1098	1106	examined	T033	UMLS:C0332128
27335087	1110	1126	Western blotting	T058	UMLS:C0005863
27335087	1142	1147	cells	T017	UMLS:C0007634
27335087	1151	1158	tissues	T017	UMLS:C0040300
27335087	1193	1213	Alanine transaminase	T103	UMLS:C0001899
27335087	1215	1218	ALT	T103	UMLS:C0001899
27335087	1221	1243	aspartate transaminase	T103	UMLS:C0004002
27335087	1245	1248	AST	T103	UMLS:C0004002
27335087	1251	1270	blood urea nitrogen	T103	UMLS:C0600137
27335087	1272	1275	BUN	T103	UMLS:C0600137
27335087	1282	1292	creatinine	T103	UMLS:C0010294
27335087	1294	1297	CRE	T103	UMLS:C0010294
27335087	1304	1312	detected	T033	UMLS:C0442726
27335087	1341	1349	analyzer	T074	UMLS:C0179038
27335087	1375	1379	FZQJ	T103	UMLS:C0574031
27335087	1393	1398	serum	T031	UMLS:C0229671
27335087	1420	1433	proliferation	T038	UMLS:C0596290
27335087	1437	1448	HepG2 cells	T017	UMLS:C2717940
27335087	1497	1507	HepG2 cell	T017	UMLS:C2717940
27335087	1508	1517	apoptosis	T038	UMLS:C0162638
27335087	1543	1545	Δψ	T038	UMLS:C1720920
27335087	1547	1555	Analysis	T062	UMLS:C0936012
27335087	1559	1571	tumor tissue	T017	UMLS:C0475358
27335087	1584	1588	FZQJ	T103	UMLS:C0574031
27335087	1599	1608	apoptosis	T038	UMLS:C0162638
27335087	1628	1642	downregulation	T038	UMLS:C0013081
27335087	1646	1651	Bcl-2	T103	UMLS:C0210955
27335087	1656	1668	upregulation	T038	UMLS:C0041904
27335087	1672	1675	Bax	T103	UMLS:C0219474
27335087	1688	1700	cytochrome c	T103	UMLS:C0010749
27335087	1702	1712	activation	T038	UMLS:C0014429
27335087	1716	1725	caspase 3	T103	UMLS:C0291573
27335087	1730	1731	9	T103	UMLS:C0910167
27335087	1737	1745	cleavage	T038	UMLS:C0597304
27335087	1749	1753	PARP	T103	UMLS:C0032405
27335087	1768	1772	FZQJ	T103	UMLS:C0574031
27335087	1802	1810	CD4(+) T	T017	UMLS:C0039215
27335087	1815	1823	NK cells	T017	UMLS:C0022688
27335087	1838	1844	CD4(+)	T017	UMLS:C0039215
27335087	1847	1861	CD8(+) T cells	T017	UMLS:C0242629
27335087	1887	1892	serum	T031	UMLS:C0229671
27335087	1893	1898	TNF-α	T103	UMLS:C0041368
27335087	1900	1904	FZQJ	T103	UMLS:C0574031
27335087	1920	1924	CD69	T103	UMLS:C0108800
27335087	1925	1935	expression	T038	UMLS:C1171362
27335087	1939	1951	tumor tissue	T017	UMLS:C0475358
27335087	1953	1976	No hepatorenal toxicity	T033	UMLS:C0243095
27335087	1993	2015	H22 tumor-bearing mice	T038	UMLS:C1512411
27335087	2031	2040	indicated	T033	UMLS:C1444656
27335087	2046	2050	FZQJ	T103	UMLS:C0574031
27335087	2069	2075	growth	T038	UMLS:C0220844
27335087	2109	2124	immune function	T038	UMLS:C1817756
27335087	2138	2150	mitochondria	T017	UMLS:C0026237
27335087	2160	2169	apoptosis	T038	UMLS:C0162638